Intestinal Stem Cells and Colon Cancer: Biology to Therapy

Sept. 27-30, 2018
Capital Hilton
Washington, District of Columbia

Conference Cochairs
Anil K. Rustgi, University of Pennsylvania, Philadelphia, Pennsylvania
Johanna C. Bendell, Sarah Cannon Research Institute, Nashville, Tennessee
Hans Clevers, Hubrecht Institute, Utrecht, Netherlands
Christina Curtis, Stanford University, Stanford, California
Owen Sansom, Beatson Institute for Cancer Research, Glasgow, United Kingdom


Non-hematopoietic tissue stem cells have garnered much attention in recent years, especially in the intestine/colon. Wnt and Notch signaling are critical in the regulation of cell lineages (absorptive vs. secretory) that emerge from these stem cells, whereas Hedgehog and other pathways are crucial for signals from the mesenchyme. These pathways influence the constitution of the stem cell niche. Stem cells can now be modeled in 3D organoid cultures, permitting the investigation of morphogenesis, elucidating the impact of developmental pathways and live cell imaging, and testing of therapeutics individually and in combination. It has been demonstrated that intestinal stem cells have the capacity to undergo malignant transformation, resulting in colon cancer. Genetic and epigenetic alterations in a variety of signaling pathways are responsible for the initiation and progression of colon cancer. In addition to these noted alterations, four consensus molecular classifications (CMS) subtypes summarize distinguishing features of colorectal cancer lesions. As a result, opportunities abound for translation into new avenues for early detection, risk stratification, and innovative therapies (targeted therapeutics and immunotherapy). This exciting AACR conference will appeal to students, fellows, scientists, physicians, industry representatives, and government officials.


Continuing Medical Education Activity AMA PRA Category 1 CreditsTM available